The Sapheon Closure System Feasibility Study
This study has been completed.
Information provided by (Responsible Party):
First received: May 18, 2012
Last updated: September 24, 2014
Last verified: September 2014
This is a single center, prospective, non-randomized, feasibility study for the evaluation of safety, efficacy and performance of the Sapheon™ Closure System for the treatment of incompetent saphenous veins.
Venous Insufficiency of Leg
||Observational Model: Cohort
Time Perspective: Prospective
||The Sapheon Closure System Feasibility Study
Primary Outcome Measures:
Secondary Outcome Measures:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||July 2012 (Final data collection date for primary outcome measure)
Venous insufficiency of the lower extremities is a very common condition that is influenced by genetic and mechanical factors, and is a chronic and progressive disorder. The primary objectives for this clinical Study are to
- demonstrate the safety of the Sapheon™ Closure System for the treatment of incompetent saphenous veins,
- demonstrate the early and late efficacy of The Sapheon™ Closure System for the treatment of incompetent saphenous veins, and
- demonstrate the satisfactory performance of the Sapheon™ Closure System device components.
|Ages Eligible for Study:
||21 Years to 76 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
All patients with venous leg insufficiency presenting themselves at the hospital vein clinic and or physicians office will be evaluated to inclusion.
- Males or non-pregnant females ≥21 years of age but <76 years of age.
- Venous reflux disease in the GSV diagnosed by clinical symptoms, with or without visible varicosities, and confirmed by duplex ultrasound imaging.
- Candidate for surgical closure of a segment of the GSV.
- CEAP classification of C2, C3 or C4.
- Ability to walk unassisted.
- Life expectancy of at least 18 months.
- Ability to attend follow-up visits.
- Ability to understand the investigational nature of the treatment, and to provide written informed consent.
- Previous surgical procedure (surgical, thermal, or chemical ablation) associated with the venous segment to be treated.
- Diameter of index vein (Supine) <3mm or >12 mm in any segment.
- Tortuous GSV, which in the opinion of the Investigator will limit catheter placement.
- Local or systemic infection.
- Insulin dependent diabetes.
- Leg obesity impairing the ability to gain access to the treatment leg, and/or apply sufficient compression for treatment.
- Documented history of superficial or deep thrombophlebitis.
- Varicosities secondary to pelvic or abdominal tumor.
- Significant arterial insufficiency; demonstrated by absence of ankle pulse.
- Known sensitivity to the cyanoacrylate (CA) adhesive or positive reaction just prior to surgery (by injecting a small peripheral vein with the agent). The Study surgeon will judge the need for the injection and the subject's reaction to the injection on clinical grounds.
- Formal duplication of the saphenous trunk in the index vein (Accessory GSV segments allowed).
- Hypercoaguable state.
- Presence of incompetent perforators in the treatment length.
- History of right ventricular failure.
- Significant femoral or popliteal vein insufficiency.
- Additional procedures in the treatment leg likely required within the six months after the investigational procedure.
- Current participation in another clinical study involving an investigational agent or treatment, or within the 30 days prior to enrollment.
- Other concurrent medical or other condition (chronic or acute in nature) that in the opinion of the Investigator may prevent safe participation or otherwise render the subject ineligible for the Study.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01603433
|Santo Domingo, Dominican Republic |
||Claudia Bautista, MD
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||May 18, 2012
||September 24, 2014
||Dominican Republic: Consejo Nacional de Bioetica en Salud
Dominican Republic: Secretaría del Estado de Salud Pública y Asistencia Social (SESPAS)
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on November 30, 2015